Globus Medical Competitors

Abbott Laboratories (NYSE:ABT) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Risk and Volatility

Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Institutional and Insider Ownership

63.9% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 66.6% of Globus Medical shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by insiders. Comparatively, 25.6% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Abbott Laboratories and Globus Medical's gross revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Globus Medical. Abbott Laboratories is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Abbott Laboratories and Globus Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Abbott Laboratories and Globus Medical, as provided by MarketBeat.com.

Abbott Laboratories presently has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Globus Medical has a consensus price target of $60.2857, suggesting a potential upside of 3.11%. Given Abbott Laboratories' higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Globus Medical.

Summary

Globus Medical beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Globus Medical (NYSE:GMED) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Earnings & Valuation

This table compares Medtronic and Globus Medical's gross revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Globus Medical. Medtronic is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Medtronic has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Medtronic and Globus Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for Medtronic and Globus Medical, as provided by MarketBeat.com.

Medtronic presently has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Globus Medical has a consensus price target of $60.2857, suggesting a potential upside of 3.11%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Globus Medical.

Institutional and Insider Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 66.6% of Globus Medical shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 25.6% of Globus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Medtronic beats Globus Medical on 10 of the 15 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Stryker (NYSE:SYK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Globus Medical and Stryker's revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Globus Medical. Stryker is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Stryker's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Stryker, as reported by MarketBeat.com.

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Stryker has a consensus target price of $221.44, suggesting a potential downside of 4.97%. Given Globus Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Globus Medical is more favorable than Stryker.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Globus Medical beats Stryker on 8 of the 15 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Globus Medical and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Intuitive Surgical's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Intuitive Surgical, as reported by MarketBeat.com.

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Intuitive Surgical has a consensus target price of $718.2778, suggesting a potential downside of 0.11%. Given Globus Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Globus Medical is more favorable than Intuitive Surgical.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Intuitive Surgical beats Globus Medical on 11 of the 14 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Globus Medical and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Becton, Dickinson and has higher revenue and earnings than Globus Medical. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Becton, Dickinson and's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Becton, Dickinson and, as reported by MarketBeat.com.

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Becton, Dickinson and has a consensus target price of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's higher possible upside, analysts clearly believe Becton, Dickinson and is more favorable than Globus Medical.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Becton, Dickinson and beats Globus Medical on 8 of the 15 factors compared between the two stocks.

Globus Medical (NYSE:GMED) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Globus Medical and Edwards Lifesciences, as reported by MarketBeat.com.

Globus Medical currently has a consensus target price of $60.2857, suggesting a potential upside of 3.11%. Edwards Lifesciences has a consensus target price of $87.7222, suggesting a potential upside of 3.57%. Given Edwards Lifesciences' higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Globus Medical.

Insider & Institutional Ownership

66.6% of Globus Medical shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 25.6% of Globus Medical shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Globus Medical and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Globus Medical has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and Edwards Lifesciences' net margins, return on equity and return on assets.

Summary

Edwards Lifesciences beats Globus Medical on 11 of the 14 factors compared between the two stocks.